Comparing Rifampicin Combination Therapy to Clindamycin Monotherapy
for Oral Treatment of Staphylococcal Prosthetic Hip or Knee Joint Infection
Led by Leiden University Medical Center · Updated on 2023-12-15
316
Participants Needed
13
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatments for staphylococcal prosthetic joint infections in this Dutch multicenter clinical trial. The study compares two oral antibiotic approaches given after initial surgery to remove infection rifampicin combined with levofloxacin versus clindamycin alone. The goal is to determine whether the combination therapy is at least as effective as monotherapy by checking treatment success one year after finishing antibiotics. This trial uses a randomized open-label design and follows patients for a total of 15 months from their initial surgery.
Participants receive either rifampicin 450 mg twice daily plus levofloxacin 500 mg twice daily, or clindamycin 600 mg three times daily during a 12-week oral antibiotic treatment phase. All patients have hip or knee prosthetic joint infections caused by Staphylococcus species and are treated with a debridement, antibiotics, and implant retention DAIR surgical strategy. The study excludes patients with contraindications to the antibiotics, complicated bloodstream infections, or other specific medical conditions.
During the study, participants will be monitored through quality of life questionnaires given at baseline, 6 weeks, and 3 months after surgery. Researchers will track adverse events, antibiotic switches, development of antibiotic resistance, and any recurrence of infection or need for additional surgery. The primary outcome is treatment success measured 15 months after surgery, defined by no infection-related surgery, no new antibiotic treatment, no ongoing antibiotics, and survival. The total follow-up lasts approximately 15 months after the initial surgical intervention.
CONDITIONS
Brief Title
Rifampicin Combination Therapy Versus Monotherapy for Staphylococcal Prosthetic Joint Infection
Research Team
H
Henk Scheper, MD
M
Mark De Boer, MD PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Confirmed staphylococcal prosthetic hip or knee joint infection by EBJIS 2021 definition
Infection caused by Staphylococcus aureus and/or coagulase-negative staphylococci
Treatment following the DAIR procedure
You will not qualify if you...
Contraindication for rifampicin (e.g., resistant strain, allergy, drug interactions)
Complicated Staphylococcus aureus bacteremia or endocarditis requiring over 2 weeks of intravenous antibiotics
Infection lacking suitable oral antibiotic options for study randomization
Treatment failure before starting oral therapy
Need to continue intravenous antibiotics beyond 21 days due to poor response
Expected life expectancy less than 12 months
Presence of tumor prosthesis
Receiving chemotherapy for active cancer within next 12 months
Scheduled for chronic suppressive antibiotic therapy over 12 months
Unlikely to comply with trial requirements after randomization
Pregnancy
Unable to read or communicate in Dutch or English
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
screening and enrollment visit
Treatment
Duration - 12 weeks
Participants receive oral antimicrobial treatment with either rifampicin-based combination therapy or clindamycin monotherapy for staphylococcal prosthetic joint infection.
Visits at the time of randomization, week 6 after surgical debridement, and week 12
Follow-up
Duration - Up to 15 months from initial surgical debridement
Participants are monitored for treatment success and adverse events after completing antibiotic treatment.
Follow-up assessments including quality of life and safety monitoring during this period
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Longitudinal Evaluation of Outcomes After Knee and Hip Arthroplasty Surgery to Improve Patient Care
Study of PLG0206 to Prevent Recurrent Infection in Adults Undergoing DAIR Surgery for Prosthetic Joint Infection After Knee Replacement
Study on Irrigation Volumes Using Methylene Blue Dye During Knee Replacement Surgery to Clear Contamination
Comparison of Durable Real-Component versus All-Cement Articulating Spacers
for Treating Chronic Periprosthetic Knee Infection
Using Antibiotic Cement and Intravenous Antibiotics
Comparing Rifampicin Combination Therapy to Clindamycin Monotherapy
for Oral Treatment of Staphylococcal Prosthetic Hip or Knee Joint Infection
Feasibility Study of Early Prosthesis Reimplantation Within 16 to 30 Days After Implant Removal for Hip or Knee Joint Infection
Study of Probiotics Added to Standard Treatment for Prosthetic Joint Infection of the Hip and Knee to Improve Immune Response and Patient Outcomes
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Outcome of Debridement, Antibiotics, and Implant Retention for Staphylococcal Hip and Knee Prosthetic Joint Infections, Focused on Rifampicin Use: A Systematic Review and Meta-Analysis.